2-Chloro-5-iodopyrazine

2-Chloro-5-iodopyrazine Property

Boiling point:

250.2±35.0 °C(Predicted)

Density 

2.187±0.06 g/cm3(Predicted)

storage temp. 

under inert gas (nitrogen or Argon) at 2–8 °C

pka

-4.25±0.10(Predicted)

Appearance

White to yellow Solid

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P321Specific treatment (see … on this label).

P330Rinse mouth.

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P362Take off contaminated clothing and wash before reuse.

P501Dispose of contents/container to..…

2-Chloro-5-iodopyrazine Chemical Properties,Usage,Production

Uses

2-Chloro-5-iodopyrazine is a pharmaceutical intermediate that has been reported in the literature to be used in the preparation of estrogen receptor covalent antagonists and orexin receptor modulators.

Application

2-Chloro-5-iodopyrazine can be used to prepare tetrasubstituted olefin compounds having the following structure. These compounds are estrogen receptor covalent antagonists. These compounds can be used to inhibit the growth of cell cultures of MCF7ER-alpha (wild-type) and MCF7ER-alpha (Y537S mutant) cells. Other compounds known to inhibit the growth of cell cultures of MCF7ER-alpha (wild-type) cells (e.g., tamoxifen, raloxifene, and fulvestrant) are currently used to treat breast cancer in human patients. Therefore, the compounds disclosed herein can be used to treat breast cancer expressing ER-alpha in human patients, and specifically, to treat breast cancer expressing Y537S mutant ER-alpha in human patients.